Last reviewed 2026-04-23 · How we verify

Any FDA Approved ALK Inhibitors

Takeda · Phase 2 active Small molecule

Any FDA Approved ALK Inhibitors is a ALK inhibitor Small molecule drug developed by Takeda. It is currently in Phase 2 development for Non-small cell lung cancer.

ALK tyrosine kinase inhibitor

ALK tyrosine kinase inhibitor Used for Non-small cell lung cancer.

At a glance

Generic name	Any FDA Approved ALK Inhibitors
Sponsor	Takeda
Drug class	ALK inhibitor
Target	ALK
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

Inhibits the activity of the anaplastic lymphoma kinase (ALK) protein, which is involved in the development and progression of certain cancers.

Approved indications

Non-small cell lung cancer

Common side effects

Diarrhea
Nausea
Vomiting
Fatigue
Weight loss

Key clinical trials

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Any FDA Approved ALK Inhibitors CI brief — competitive landscape report
Any FDA Approved ALK Inhibitors updates RSS · CI watch RSS
Takeda portfolio CI

Frequently asked questions about Any FDA Approved ALK Inhibitors

What is Any FDA Approved ALK Inhibitors?

Any FDA Approved ALK Inhibitors is a ALK inhibitor drug developed by Takeda, indicated for Non-small cell lung cancer.

How does Any FDA Approved ALK Inhibitors work?

ALK tyrosine kinase inhibitor

What is Any FDA Approved ALK Inhibitors used for?

Any FDA Approved ALK Inhibitors is indicated for Non-small cell lung cancer.

Who makes Any FDA Approved ALK Inhibitors?

Any FDA Approved ALK Inhibitors is developed by Takeda (see full Takeda pipeline at /company/takeda).

What drug class is Any FDA Approved ALK Inhibitors in?

Any FDA Approved ALK Inhibitors belongs to the ALK inhibitor class. See all ALK inhibitor drugs at /class/alk-inhibitor.

What development phase is Any FDA Approved ALK Inhibitors in?

Any FDA Approved ALK Inhibitors is in Phase 2.

What are the side effects of Any FDA Approved ALK Inhibitors?

Common side effects of Any FDA Approved ALK Inhibitors include Diarrhea, Nausea, Vomiting, Fatigue, Weight loss.

What does Any FDA Approved ALK Inhibitors target?

Any FDA Approved ALK Inhibitors targets ALK and is a ALK inhibitor.

Drug class: All ALK inhibitor drugs
Target: All drugs targeting ALK
Manufacturer: Takeda — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Non-small cell lung cancer
Compare: Any FDA Approved ALK Inhibitors vs similar drugs
Pricing: Any FDA Approved ALK Inhibitors cost, discount & access